← back to problem page
Whitepaper · v0.1·hard tech·open to refutation

An optimism.fun request for startups

Longevity & aging

Aging drives most disease. Slow it and most diseases recede.

Published

2026-04-24

Authors

optimism.fun

Status

Draft · v0.1

License

CC BY 4.0

§0weekly drop · week 1

Editor’s drop

Published 2026-08-20 · optimism.fun

blackpaper · the problem

Aging is the single largest risk factor for human death, and it is currently untreated. Every one of the 8.1 billion humans alive is aging on the same clock (UN Population Division, 2026). Aging is the upstream cause of the diseases that actually kill people: cardiovascular disease, cancer, neurodegeneration, and frailty all share aging biology as a common driver, not four unrelated problems (Lopez-Otin et al., "Hallmarks of Aging," Cell, 2022). Medicine treats the downstream diseases one at a time and has gotten very good at postponing death from any single one of them. It has made almost no progress on the clock itself. The result is a long tail of decline that current medicine does not fix, it just extends. Global life expectancy has climbed from 32 years in 1900 to 73 today (Our World in Data / UN), which is real progress and worth stating plainly. But healthspan, the years lived without serious functional decline, has not kept pace with lifespan. Healthspan starts dropping around age 50 in most people, well before life ends. Roughly 100 million people worldwide are living with frailty-driven decline right now, a population larger than most countries, and growing every year as the global population ages (UN World Population Prospects). The direct cost is concentrated and enormous. Roughly a quarter of a person's lifetime healthcare spending occurs in the final decade of life (OECD Health Statistics), most of it treating the consequences of aging rather than aging itself. Globally, healthcare spend on people 65 and older runs around $4 trillion a year (OECD Health Statistics, 2026 estimate). That is not a market size, it is the cost of not solving the problem: money spent managing decline instead of preventing it. The honest state of the science: there is no FDA-approved intervention that slows human aging today. Rapamycin, metformin-class geroprotectors, senolytics, and partial epigenetic reprogramming have shown effects in animal models, in some cases dramatic ones (mouse lifespan extension of 20 to 60 percent under caloric restriction mimetics and senolytic clearance, per Buck Institute-affiliated research), but none has cleared human trials as a life-extension therapy, because "aging" is not yet a regulatory indication the FDA recognizes. That is a policy gap as much as a science gap. Aging biology is also underfunded relative to its share of total disease burden. Disease-by-disease research (oncology, cardiology, neurology) attracts far more capital than research into the shared upstream cause, despite aging biology plausibly being the more leveraged place to intervene (Hevolution Foundation). This is the frontier that Founders Fund's "Choose Good Quests" thesis is pointing at: important if it works, genuinely still open, and unambiguously good, since nobody is made worse off by other people living healthier longer. This is a blackpaper, not a pitch: the honest state is that the biology is promising in animals and unproven in humans, the regulatory path does not exist yet, and 8.1 billion people are aging while it gets built.

whitepaper · the proposal

The unlock: after two decades of foundational aging biology (Sinclair, Kenyon, the Hallmarks of Aging framework), the field now has, for the first time, tools that can be tested in humans, not just mice. Partial cellular reprogramming (Altos Labs, Retro Biosciences, NewLimit) can reverse epigenetic age markers in cell culture without erasing cell identity. Aging clocks (Morgan Levine and others) can now measure biological age from a blood draw with enough precision to serve as a trial endpoint, which is the actual bottleneck: the FDA has historically had no way to approve a drug for "slowing aging" because there was no accepted way to measure whether it worked in a human timeframe shorter than decades. A validated biomarker of aging is what turns "aging" into a legible, trialable, fundable indication. That single unlock is why this field is buildable now in a way it was not ten years ago. What actually needs to get built, concretely: 1. A validated, FDA-accepted biological-age biomarker panel that can serve as a surrogate trial endpoint, so a geroprotective drug can be tested and approved in years rather than the multi-decade lifespan studies aging would otherwise require. 2. Clinical trials for the existing geroprotector class (rapamycin analogs, senolytics, NAD+ precursors) run against that endpoint, at a scale current biotech has not attempted because there was no regulatory path. 3. A delivery layer: today, access to the diagnostics and off-label protocols that exist is gated behind $10,000 to $85,000-a-year concierge longevity clinics like Fountain Life (Fountain Life, World Longevity Clinics 2026 pricing survey), which by construction reach only the wealthiest few thousand people on earth. The mass-market version of this, a diagnostics-plus-protocol subscription priced for a much larger population, does not exist yet. The dollar value, worked from real numbers rather than restated: Start from the population that would actually buy a longevity product: adults 50 and older, globally. The UN estimates roughly 1.7 billion people are 50+ worldwide as of the mid-2020s (UN World Population Prospects, age-structure tables). AARP's Longevity Economy Outlook found that 78 percent of US adults over 50 say they are willing to pay a premium for products that credibly extend healthy lifespan (AARP Longevity Economy Outlook), which is directional evidence of real willingness to pay, not just interest. Existing concierge longevity clinics charge $10,000 to $85,000 a year and are already profitable at that price with a client base in the low thousands (Fountain Life, World Longevity Clinics 2026 cost guides). That price point cannot scale to a billion people. But a mass-market version, an annual biomarker panel plus a prescribed, evidence-backed protocol (not the full concierge experience) is a realistic $500 to $1,500 a year, closer to a premium gym membership or a high-end health-insurance add-on than a concierge clinic. Call it $1,000 a year as the realistic mass-market price point. Even a conservative 10 percent penetration of the global 50+ population, 170 million people, at $1,000 a year, is a $170 billion-a-year market. That is a rough, low-confidence estimate (penetration rate is a guess, not a survey finding), but it is triangulated from real numbers: a real population count (UN), a real stated willingness to pay (AARP), and a real anchor price from clinics operating today (Fountain Life). It sits comfortably inside the existing, more conservative framing in this project's own problem data, which cites the standalone longevity-tech market growing from $44 billion to $600 billion by 2035, and is far smaller than the $4 trillion in global healthcare spend on the 65+ population that the disease burden already represents (OECD Health Statistics). The $170B figure is the addressable near-term commercial wedge; the $4T is the cost the wedge is cutting into. Who backs this: existing capital (Altos Labs, funded at a level rumored above $3 billion; Hevolution Foundation's multi-billion-dollar aging-research commitment) is already flowing into the underlying biology. What is missing is capital and founders willing to build the boring middle layer, the validated biomarker panel and the mass-market delivery company, rather than the next reprogramming biotech. That is the open quest here: not "cure aging," but "build the diagnostic and delivery infrastructure that lets 170 million people, not 2,000, buy into the biology that already works in mice." Conjecture, open to refutation: the $170B figure depends on both the 10 percent penetration assumption and the $1,000 price point holding at scale, neither of which has been tested by any company yet. Flag it as the honest weak point in this estimate.
§1abstract

The four-axis ranking

We rank humanity’s most important problems on four quantifiable dimensions — quantity of humans affected, severity per person, current solution quality, and addressable market size — and package each as a proposal in the spirit of Musk’s Hyperloop Alpha. This document is the proposal for longevity & aging. Every number below is sourced and tagged with confidence. Every ranking is a conjecture, open to refutation.

Quantity · humans affected

8.1B

high

Severity · 0–1

unknown

Current solutions

2.0 / 10

low

Market size · TAM

$4.0T

med
§2problem statement

What we are trying to solve

Aging underlies cardiovascular disease, cancer, neurodegeneration, and frailty. Every human alive is affected. The hallmarks-of-aging framework (López-Otín et al.) gives discrete targets: senescent cell clearance, epigenetic reprogramming, stem cell exhaustion. Partial cellular reprogramming (Altos, Retro, NewLimit) and geroprotective drugs (rapamycin, metformin class) are in early trials. Utility delta is enormous: current median healthspan ~75 years, theoretical ceiling unknown and likely much higher.

§3why it persists

The gap between the world and the world that is physically possible

Today: Healthspan declines starting ~age 50. Aging treated as inevitable rather than as a disease. ~100M humans living with frailty-driven decline.

Current solution quality is rated 2.0 / 10 (low confidence) — meaning there is substantial unclaimed ground between what exists and what is possible. estimated — rapamycin, senolytics promising in mice; no FDA-approved life-extension intervention yet.

§4existing alternatives

Who is already working on this

8 entities are currently working on this problem across public markets, private companies, and research orgs. Each is evidence the market is real; none has obviously solved it.

AI-driven drug discovery. Industrializes biology through automated phenotypic screening at scale.

$2.4B

Colossal Biosciences

private · USA

De-extinction and genetic engineering. Biosecurity adjacency via rapid genome editing and cold-chain logistics.

$10.2B

Altos Labs

private · USA

Cellular rejuvenation via partial reprogramming. $3B at founding with Shinya Yamanaka on scientific board.

$3.0B

Isomorphic Labs

private · UK

Alphabet-spinoff applying AlphaFold-class ML to drug design. Deals with Novartis and Eli Lilly.

undisclosed

Calico Life Sciences

private · USA

Alphabet company for aging biology. Research partnership with AbbVie; long-horizon mandate rare in pharma.

undisclosed

Retro Biosciences

private · USA

Cellular reprogramming, autophagy, and plasma-exchange therapeutics. Seed-funded by Sam Altman at $180M.

undisclosed

NewLimit

private · USA

Partial reprogramming for aging, started by Blake Byers, Jacob Kimmel, and Brian Armstrong.

undisclosed

Loyal

private · USA

FDA-track longevity drug for dogs. First-of-its-kind lifespan-extension regulatory pathway.

undisclosed

§5proposed direction

If we solve this, here is the world we get

After · 30 years

Healthspan extended by 20+ years. Aging recognized as a treatable condition with FDA-approved interventions. 100→120-year healthy lifespan common in cohorts born after 2030.

Requests for startups · 2 concrete companies to build

Aging as an FDA-recognized indication

You cannot run a trial for a disease the regulator does not recognize. Build the company that runs the TAME-class trial and operationalizes aging biomarkers as approvable endpoints.

why now
Biomarker science (epigenetic and proteomic clocks) matured enough to be candidate endpoints; the regulatory path is the remaining frontier.
shape
A clinical-stage company designing and running the pivotal trial plus the regulatory-science work to make "aging" a legitimate, reimbursable indication.
success
Aging is a recognized indication with at least one approved intervention and validated endpoints.

The healthspan diagnostic

Medicine measures disease, not the slope of decline. You cannot manage what you do not measure. Build the longitudinal aging-clock and intervention-tracking company.

why now
Multi-omic aging clocks became reproducible enough to track individual trajectories over time.
shape
A consumer + clinical diagnostic that measures biological aging longitudinally and quantifies whether an intervention is bending the curve.
success
Individuals and trials can see, in months, whether an intervention slows aging.

full rubric + framing on the Requests for Startups page.

§6cost & scale

What the market can pay

The world is already paying $4.0T per year against this problem (global healthcare spend for ages 65+ (OECD Health Statistics); standalone longevity-tech market projected $44B → $600B by 2035; med confidence).

A successful solution does not need to capture more — it needs to redirect a meaningful slice of existing spend, plus the latent willingness-to-pay implied by the severity score above. The cost ceiling for a real solution is bounded by this number; everything cheaper is dominated, everything more expensive is a non-starter.

§7safety & considerations

What could go wrong, and how we know we are not wrong

Section in progress

Failure modes, ethical considerations, and the conditions under which this whitepaper would be falsified are being authored as the weekly cadence ships. The Deutschian commitment: every claim above is a conjecture; we publish the conditions under which we would update. Unpublished sections stay empty. A Monday newsletter is not promised. Subscribe to get the upgrade, or contribute on GitHub.

§8suggested investors

Who would back this

Capital allocators with a stated thesis or deployed portfolio in this domain. This is a starting list — Exa Websets enrichment will expand it to direct check-writers per company.

Grant

Emergent Ventures

Fast grants. High-variance, unconventional, talent-first.

Fellowship

Thiel Fellowship

$100k to stop out of school and build something important.

Venture Studio

Deep Science Ventures

Outcome-first venture creation. Define the holy-grail outcome, then recruit founders.

Venture Capital

Founders Fund

Contrarian hard tech that rebuilds the industrial base.

Venture Capital

Lux Capital

Counter-conventional science at the edges of physics and biology.

§9voices

What the thinkers say

“Neuralink targets brain and spinal-cord disease as near-term deliverables with long-term implications for human-AI symbiosis and healthspan.”

— Elon Musk · Engineer & Founder

“Extending healthy human life is a core progress goal. Curing aging is as legitimate a target as curing any single disease.”

— Jason Crawford · Founder

“Human lifespan extension is on the canonical list of "good quests that require massively leveled heroes."”

— Trae Stephens · Partner & Co-founder
§10sources & criticism invite

Where this is wrong, tell us

Every number on this page carries a source and a confidence tag. Every section open to refutation. If a citation is wrong, a number is stale, or a conjecture is unfounded — file a correction.

corrections → use the feedback widget in the nav · open issue at github.com/adamtpang/optimism.fun

Published whitepapers

One problem.Published essays, not a Monday promise.

The essays that exist are listed at /whitepapers. A new essay is not promised every Monday. Weeks with no essay are empty on purpose. Nothing here invents a back catalog.

optimism.fun uses your email address only to send low-volume project updates through Resend. You can unsubscribe with one click at any time; read the privacy policy.